CL2019001674A1 - Inhibidores de imidazopirazina de tirosina quinasa de bruton. - Google Patents
Inhibidores de imidazopirazina de tirosina quinasa de bruton.Info
- Publication number
- CL2019001674A1 CL2019001674A1 CL2019001674A CL2019001674A CL2019001674A1 CL 2019001674 A1 CL2019001674 A1 CL 2019001674A1 CL 2019001674 A CL2019001674 A CL 2019001674A CL 2019001674 A CL2019001674 A CL 2019001674A CL 2019001674 A1 CL2019001674 A1 CL 2019001674A1
- Authority
- CL
- Chile
- Prior art keywords
- imidazopyrazine
- bruton
- compounds
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
EN ALGUNAS MODALIDADES, LA INVENCIÓN SE RELACIONA CON LOS COMPUESTOS DE FÓRMULA (I) Y (II), O ALGUNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, O CON COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS Y CON SU USO TERAPÉUTICO. ESPECÍFICAMENTE, EN ALGUNAS MODALIDADES, LA PRESENTE INVENCIÓN SE RELACIONA CON LOS COMPUESTOS DE FÓRMULA (I) Y (II), SUS COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS COMPUESTOS Y LAS COMPOSICIONES FARMACÉUTICAS EN EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO, UN TRASTORNO INFLAMATORIO, UN TRASTORNO INMUNITARIO O UN TRASTORNO AUTOINMUNITARIO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437633P | 2016-12-21 | 2016-12-21 | |
| US201762569028P | 2017-10-06 | 2017-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001674A1 true CL2019001674A1 (es) | 2019-11-08 |
Family
ID=60972291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001674A CL2019001674A1 (es) | 2016-12-21 | 2019-06-18 | Inhibidores de imidazopirazina de tirosina quinasa de bruton. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10858364B2 (es) |
| EP (1) | EP3558968B1 (es) |
| JP (1) | JP7022131B2 (es) |
| KR (1) | KR102559851B1 (es) |
| CN (1) | CN110291080B (es) |
| AU (1) | AU2017383236B2 (es) |
| CA (1) | CA3046578A1 (es) |
| CL (1) | CL2019001674A1 (es) |
| ES (1) | ES2856248T3 (es) |
| IL (1) | IL267374B (es) |
| MX (1) | MX388457B (es) |
| MY (1) | MY203083A (es) |
| SA (1) | SA519402217B1 (es) |
| WO (1) | WO2018116259A1 (es) |
| ZA (1) | ZA201903932B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3394033B1 (en) | 2015-12-22 | 2020-11-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| MA47123A (fr) | 2016-12-22 | 2021-03-17 | Incyte Corp | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| PL4212529T3 (pl) | 2018-03-30 | 2025-07-07 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| HRP20230306T1 (hr) | 2018-05-11 | 2023-05-12 | Incyte Corporation | Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori |
| WO2019243964A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| IL312413B1 (en) | 2018-08-29 | 2025-09-01 | Acerta Pharma Bv | Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| IL291471B2 (en) | 2019-09-30 | 2025-04-01 | Incyte Corp | Pyrimido[3,2–D]pyrimidine compounds as immunomodulators |
| CR20220237A (es) | 2019-11-11 | 2022-08-05 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| CN114075190A (zh) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| AR124001A1 (es) | 2020-11-06 | 2023-02-01 | Incyte Corp | Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
| EP4631503A1 (en) * | 2024-04-08 | 2025-10-15 | Molius Saglik Teknolojileri Anonim Sirketi | Avl-292 or mk-5108 for use in the treatment of pdac |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2526934B1 (en) * | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CN102428087B (zh) * | 2009-04-16 | 2015-06-17 | 卡洛斯三世国家癌症研究中心基金会 | 用作激酶抑制剂的咪唑并吡嗪类化合物 |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| EP3495368B1 (en) * | 2011-07-19 | 2023-05-31 | Merck Sharp & Dohme B.V. | (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor |
| EP2734523A1 (en) * | 2011-07-19 | 2014-05-28 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| EP3076974A1 (en) * | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| US20170231995A1 (en) * | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
| WO2016106623A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
| WO2016106627A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| MA42623A (fr) * | 2015-06-02 | 2018-06-20 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
-
2017
- 2017-12-21 US US16/448,056 patent/US10858364B2/en active Active
- 2017-12-21 WO PCT/IB2017/058319 patent/WO2018116259A1/en not_active Ceased
- 2017-12-21 CA CA3046578A patent/CA3046578A1/en active Pending
- 2017-12-21 CN CN201780086892.3A patent/CN110291080B/zh active Active
- 2017-12-21 EP EP17829328.8A patent/EP3558968B1/en active Active
- 2017-12-21 KR KR1020197020718A patent/KR102559851B1/ko active Active
- 2017-12-21 JP JP2019533229A patent/JP7022131B2/ja active Active
- 2017-12-21 MY MYPI2019003251A patent/MY203083A/en unknown
- 2017-12-21 MX MX2019007156A patent/MX388457B/es unknown
- 2017-12-21 ES ES17829328T patent/ES2856248T3/es active Active
- 2017-12-21 AU AU2017383236A patent/AU2017383236B2/en active Active
-
2019
- 2019-06-16 IL IL267374A patent/IL267374B/en unknown
- 2019-06-18 CL CL2019001674A patent/CL2019001674A1/es unknown
- 2019-06-18 ZA ZA2019/03932A patent/ZA201903932B/en unknown
- 2019-06-19 SA SA519402217A patent/SA519402217B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL267374B (en) | 2021-07-29 |
| AU2017383236B2 (en) | 2022-02-10 |
| CN110291080A (zh) | 2019-09-27 |
| JP7022131B2 (ja) | 2022-02-17 |
| CN110291080B (zh) | 2022-07-08 |
| US20190345164A1 (en) | 2019-11-14 |
| BR112019012604A2 (pt) | 2019-11-26 |
| JP2020514264A (ja) | 2020-05-21 |
| US10858364B2 (en) | 2020-12-08 |
| ZA201903932B (en) | 2021-01-27 |
| MX388457B (es) | 2025-03-20 |
| AU2017383236A1 (en) | 2019-06-27 |
| EP3558968B1 (en) | 2021-02-03 |
| MX2019007156A (es) | 2019-09-05 |
| ES2856248T3 (es) | 2021-09-27 |
| SA519402217B1 (ar) | 2022-04-19 |
| CA3046578A1 (en) | 2018-06-28 |
| EP3558968A1 (en) | 2019-10-30 |
| KR20190095403A (ko) | 2019-08-14 |
| KR102559851B1 (ko) | 2023-07-25 |
| IL267374A (en) | 2019-08-29 |
| WO2018116259A1 (en) | 2018-06-28 |
| MY203083A (en) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
| UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| MX2016014248A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| CL2018001146A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| NI201500140A (es) | Compuestos y composiciones terapéuticos | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| SV2018005680A (es) | Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| CO2017004517A2 (es) | Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |